Lv3
240 积分 2023-07-21 加入
The inclusion of comorbidity in oncology data registries
2个月前
已关闭
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis
2个月前
已完结
Surgery versus definitive radiotherapy after induction immunochemotherapy for stage II and III non-small cell lung cancer: A multicenter, pragmatic analysis
2个月前
已完结
Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy
2个月前
已完结
Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
2个月前
已完结
Post-operative outcomes of lung resection after perioperative chemoimmunotherapy for stage IIB–IIIB non-small-cell lung cancer in the elderly: a single center real-life experience
2个月前
已完结
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
2个月前
已完结
Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms
2个月前
已完结
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC
2个月前
已完结
Lung cancer recurrence after neoadjuvant immunotherapy
2个月前
已完结
皖公网安备34019202002308
